23 March 2022
Inosi Therapeutics, a Monash University spinout backed by IP Group Australia, today announced the appointment of David Phillips as its new Executive Chair.
Mr Phillips has over four decades of experience in the global healthcare and pharmaceutical industry, having previously been a senior international marketing executive with Glaxo Wellcome, as well as a Managing Partner with GSK's Corporate Venture Fund, SR One.
He also spent over a decade at board level in Chief Business Officer roles at Argenta Discovery, The Automation Partnership and Galapagos NV.
In the latter part of his career, he was both an Executive Director and Non-Executive Director of Suda Pharmaceuticals (now Arovella, ASX: ALA).
Mr Phillips has been responsible for capital raisings globally and the execution of over 50 pharmaceutical and biotechnology deals and 10 mergers and acquisitions.
Inosi is developing a new therapeutic approach to treat fibrosis. The company, which has been spun out of Monash University, is developing first in class therapeutic Insulin Regulated Aminopeptidase (IRAP) inhibitors, that have so far demonstrated significant protective effects in preclinical animal models of diabetes-induced kidney disease and cardiovascular disease.
As Executive Chair, Mr Phillips will support Inosi’s growth and expansion into overseas markets including capital raisings and business development.
Dr Siro Perez, Head of Life Sciences at IP Group Australia, said: “We are thrilled to welcome an executive chair of David’s calibre to the Board of Inosi.
“David is an outstanding executive and leader who will bring a wealth of pharmaceutical and biotech experience as Inosi continues to develop and commercialise therapies to address fibrosis.
“His proven track record of success and skills in pharmaceutical development and commercialisation will be highly valuable in supporting the growth and international expansion of the company.”
Mr Phillips said: “I am delighted to be joining Inosi Therapeutics as Executive Chair. The company has proven it has huge potential to change the future of treatment for patients with fibrosis and related disorders.
“Founded on research from Monash University, this is a prime example of commercial translation of top Australian science and innovation.”
- ENDS -
Aileen Bodart, Cannings Strategic Communications, +61 432 160 136
Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function. Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute, and the Monash Institute of Pharmaceutical Sciences. https://www.inositherapeutics.com